Thursday, 23 April 2020

Acromegaly Market Size, Share Analysis, Strategies, Revenue And Forecasts To 2023

The major driving factors for the market are increasing prevalence of acromegaly, changing lifestyle, and increasing genetic incident of genetic diseases. Moreover, increasing prevalence of hormonal diseases, for instance, endocrine diseases, and hypopituitarism, increasing government support and rapid developments in technology have fuelled the growth of the market. On the other hand, surgical costs is high, which ranges from approximately USD 2,800 to USD 9,200, however, when averaged it is less than the cost of medications. Unavailability of precise treatment and high cost of the surgery may restrain the growth of the market.
The global acromegaly treatment market growth is expected to boost at a CAGR of ~5.2 % during the forecast period 2017-2023.
Acromegaly is a hormonal disorder that results from heavy secretion of growth hormones (GH) in the body. The pituitary gland in the brain, secretes GH. In acromegaly, the pituitary produces excessive amounts of GH. Usually the excess GH comes from benign, or noncancerous, tumors on the pituitary. These benign tumors are called adenomas. Acromegaly is one of the rare diseases, which most often diagnosed in the middle-aged adults and affects 5-8 people per 1 lakh people. If the diseases is not treated, it can result in serious illness and premature death. The most serious health consequences of the disease may result into high blood pressure, type 2 diabetes, increased risk of cardiovascular disease, arthritis, and others.
Key Players
  • Novartis AG (Switzerland),
  • Aegis Therapeutics LLC (US),
  • Chiasma Inc (US),
  • Crinetics Pharmaceuticals Inc (US),
  • Daewoong Pharmaceutical Co Ltd (South Korea),
  • Peptron Inc (South Korea),
  • Silence Therapeutics Plc (UK),
  • Strongbridge Biopharma plc (US),
  • Amryt Pharma plc (UK),
  • Foresee Pharmaceuticals LLC (US),
  • Glide Pharmaceutical Technologies Ltd (US),
  • Ionis Pharmaceuticals Inc (US),
  • Ipsen SA (France)
Segmentation
Acromegaly market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of treatment, the market is segmented into medications, surgery, radiation therapy, and others. The medication is further segmented into somatostatin analogues, dopamine agonists, growth hormone receptor antagonists, and others. The surgery is further segmented into endonasal transphenoidal surgery, and transphenoidal surgery.
On the basis of diagnosis, the market is segmented into medical imaging, medical laboratory investigations, others. The medical imaging is further segmented into radiography, magnetic resonance imaging (MRI), nuclear medicine, ultrasound, and others.
On the basis of type, the market is segmented into ectopic acromegaly, acromegaly due to growth hormone, and others.
Regional Analysis
Asia Pacific is the fastest growing acromegaly market. China, and India are the significant contributors to the market growth due to the presence of huge population base, increasing prevalence of acromegaly, rapidly growing healthcare sector, and increasing healthcare expenditure. Whereas, the Middle East & Africa holds the least Acromegaly Market share of the global market due to poor economic condition and limited availability of medical facilities in African region. The Middle East & African acromegaly market is majorly driven by the UAE, Saudi Arabia, and Kuwait.
The Americas commands the global market owing to increasing prevalence of acromegaly, large patient population, high healthcare spending, and strong government support for research & development. According to the Health Research Funding Organization, in America, over 3,000 new cases of acromegaly occurs per year.
Europe leads the second position of the global the market, which is followed by Asia Pacific. High healthcare expenditure, well developed healthcare sector, and increasing government support drives the growth of the market.
Posted by at No comments:

Wednesday, 22 April 2020

Worldwide Cardiopulmonary Disease Diagnostics and Treatment Market Ready To Set Outstanding Growth From 2019 To 2023

Market Scenario:
The cardiopulmonary disease is a general term used to describe a variety of different diseases and conditions related to heart and lungs. Cardio Vascular Disease is a complex disease with a wide variety of risk factors including those that are modifiable, such as physical inactivity, non-modifiable factors such as age, genes, congenital dispositions, and gender. Respiratory disease is a medical term that includes extreme conditions affecting the organs and tissues which make gas exchange possible in higher organisms. Depending upon the type of cardiopulmonary disease present the treatment options vary and may include changes in diet or lifestyle, use of medications issued on prescription or surgery. The most common cardiopulmonary diseases are hypertension, stroke, and coronary heart disease. Untreated, cardiopulmonary diseases can be deadly. Cardiopulmonary diseases are the major cause of death globally.
The substantial growth in the frequency of health conditions related to the lungs and heart is the key factor to boosts the growth of this market. Also, the increase in aged population and the rising frequency in cardiovascular and respiratory diseases is also anticipated to drive the global market over the forecast period. Exposure to nicotine, tobacco products, and others increases the risk of obtaining cardiopulmonary diseases.
Increase in the rise of advanced technological equipment for diagnosing the disease will drive market rate exponentially. However, the huge cost of treatment and the regulatory nature of government on pharmaceutical companies will hamper the Cardiopulmonary Disease Diagnostics and Treatment market growth.
Key Players
  • Cardinal Health
  • Cosmed Medical
  • GE Healthcare
  • Halma plc
  • Hill-Rom Holdings, Inc.
  • Koninklijke Philips N.V.
  • MGC Diagnostics Corporation
  • NIHON KOHDEN CORPORATION
  • Schiller AG
  • Masimo Corporation
  • Vyaire Medical Inc
Segmentation
The global cardiopulmonary disease diagnostics and treatment market has been segmented on the basis of disease type, type, and end-user.
On the basis of disease type, the market has been classified as cardiovascular and respiratory diseases. The cardiovascular diseases are segmented into coronary artery disease, angina pectoris, myocardial infarction, dysrhythmia, hypertension, and others. The respiratory diseases are segmented into influenza, asthma, bronchitis, emphysema, cystic fibrosis, and others.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics and rehab centers, research institutes and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis market is segmented into an electrocardiogram (ECG), Holter monitoring, echocardiogram, stress test, cardiac catheterization, cardiac computerized tomography (CT) scan, cardiac magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), stress blood pressure monitors, pulse oximeters and spirometry. The treatment market is segmented into medications. The medications segment is further sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBS), anticoagulants, antiplatelet agents and others.
The European cardiopulmonary disease diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The cardiopulmonary disease diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiopulmonary disease diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Posted by at No comments:

Global Verrucous Carcinoma Market Positive Growth And Forecasts By 2023

Market Highlights
The verrucous carcinoma market is expected to witness tremendous growth owing to the rising prevalence of oral cancer. Other key factors such as the change to sedentary lifestyle, growing consumption of alcohol, increase in smoking, and increasing incidents of sexually transmitted diseases by human papillomavirus (HPV) are contributing towards the growth of the market.  However, factors such as high cost of surgical procedures, expensive chemotherapy treatments, risks of recurrence of cancer, and the side effects associated with treatments are expected to restrict the market growth during the forecast period.
Segmentation
The global verrucous carcinoma market is segmented on the basis of diagnosis, treatment, and end-user. The verrucous carcinoma market, by diagnosis, is categorized into biopsy, endoscopy, and imaging tests. Imaging tests are categorized into computerized tomography scans, magnetic resonance imaging, and positron emission tomography scans. On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, and targeted drug therapy. The surgery category consists of surgical excision and Mohs micrographic surgery. Chemotherapy consists of bleomycin, 5-fluorouracil, cisplatin, methotrexate, and others. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.
Regional Analysis
The Americas is the largest in the market owing to the increasing prevalence of Human Papillomavirus (HPV) and growing healthcare expenditure. According to the Genital HPV Infection, Fact Sheet 2017, 79 million American adults were infected with HPV. Such a high incidence of sexually transmitted human papillomavirus (HPV) drives market growth in this region.
Europe (UK, Belgium, France, and Netherlands) is the second largest verrucous carcinoma market during the forecast period. The increasing occurrence of head and neck cancer drives the market in this region. According to Cancer Research UK in 2015, there were12061 new cases of head and neck cancer. Thus, the growing cases of head and neck cancer facilitate the market growth.
Asia-Pacific was projected to be the fastest growing region for the global verrucous carcinoma market in 2017. The market is expected to witness growth owing to the rising prevalence of smoking in this region. According to the World Health Organization in 2015, 47.6% and 33.7% of people smoked tobacco in China and Japan, respectively. This is expected to provide favorable backgrounds for the market to grow.
The Middle East and Africa accounts for the least share due to low per capita income and lack of availability of well-trained healthcare professionals. However, the rising oncology and palliative care services both at the hospital level and in the community are expected to influence the market in a positive way.
Key Players
Some of the key players in the global verrucous carcinoma market are Bristol-Myers Squibb Company (US) Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company. (US), F. Hoffmann-La Roche Ltd (Europe), Merck & Co., Inc. (US), Novartis AG (Europe), Pfizer Inc. (US), and others

Posted by at No comments:

The Gene Panel Market Staggering Double Digit Cagr Driven By Advanced & Cost Effective Technologies Forecasts Till 2023

Market Scenario
The increasing prevalence of chronic diseases such as cancer, genetic diseases, and rare diseases, increase in adoption of genetic testing, rising company initiatives, technological advancements, need for efficient prenatal diagnosis, and increasing health awareness are estimated to drive the market during the forecast period. However, factors such as expensive tests, inaccuracy in results, and security concerns of the genes are estimated to restrain the market growth during the forecast period.
Global Gene Panel Market size is expected to register a CAGR of 12.16% to reach USD 4,347.32 Million by 2025.
Segmentation
The global gene panel market is segmented on the basis of product and service, technique, design, application, and end-user. The gene panel market, by product and service, is segmented into test kits and testing services. The global gene panel market by technique is segmented into the amplicon-based approach and hybridization-based approach. The design segment is segmented into predesigned gene panels and customized gene panels. On the basis of application, the market is categorized into cancer risk assessment, pharmacogenetics, diagnosis of congenital disorders, and other applications. The cancer risk assessment segment is further sub-segmented into syndrome-specific gene panels, high-penetrance gene panels, high and moderate-penetrance gene panels, and comprehensive cancer risk panels. On the basis of end-user, the market is categorized into hospitals, diagnostic laboratories, research and academic institutes, and pharmaceutical and biotechnology companies.
Key players
Some of the key players for the global gene panel market are Thermo Fisher Scientific (US), F. Hoffmann-La Roche AG (Switzerland), Illumina, Inc., BGI (China), Agilent Technologies (US),  Integrated DNA Technologies (IDT) (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Novogene Corporation (China), Personalis (US), GATC Biotech AG (GATC Biotech) (Germany), ArcherDx (US), GeneDx., CENTOGENE AG, and others.
Regional Market Summary
The Americas dominates the global market for gene panel. The increase in the patient pool for chronic diseases, government initiatives for the development of cancer treatment, and presence of strong market players such as Thermo Fisher Scientific drive the market growth in this region. Europe (the U.K., Belgium, France, and the Netherlands) is second in the market owing to the increasing research and development activities for cancer and congenital diseases. Also, the high occurrence rate of cancer in Europe influences the market growth in Europe. According to WHO, there are 3.7 million cases of cancer in Europe every year. Furthermore, Germany is predicted to dominate the European market as there were 2, 24,089 number of deaths due to cancer in 2014. Also, technological advancements coupled with an early diagnosis of cancer is likely to drive market growth for gene panel in Germany. Asia Pacific is expected to observe growth for the global gene panel market owing to the growing prevalence of cancer and increasing health expenditure. The Middle East and Africa with the presence of low-income countries, low healthcare expenditures, and stringent government regulations accounted for the least market share.
Posted by at No comments:

Worldwide Defibrillators Pads Market Booming Industry Size And Revenue | Future Vision Footbridge 2023 In Healthcare Sector

Market Highlights
The defibrillators pads market is projected to register a CAGR of 5% during the forecast period. The defibrillation process is used as a treatment in ventricular fibrillation, pulseless ventricular tachycardia, and cardiac arrhythmia. A defibrillator is used for delivery of an electric shock to the heart that causes depolarization of the heart muscles and re-establishes normal conduction of the heart’s electrical impulse.
The global defibrillators pads market is majorly driven by the high prevalence of cardiovascular diseases, increasing advancement in surgeries, and growing penetration by market players. Additionally, factors such as initiatives taken by the government to increase the quality of healthcare, innovations in medical devices, and availability of skilled personnel are likely to spur the growth of the market. However, factors such as high cost of defibrillators pads and their implantation procedures are likely to hinder the growth of the market. Likely, limited knowledge about defibrillators and sudden cardiac arrest issues are expected to turn as a challenge for the market.
Regional Analysis
The Americas dominates the global defibrillators pads market owing to the increasing geriatric population, which leads to hypertension and metabolic disorders that trigger the occurrence of cardiovascular disorders. Additionally, increasing fast food chains, the rate of obesity issues, addiction to alcohol, and tobacco and drugs along with rising government initiatives for the research and development of innovative and advanced products are likely to enhance the growth of defibrillators pads in the North American region.  For instance, the American Heart Association estimated that 31% of the deaths in the U.S. were due to cardiovascular disorders in 2014. The presence of some of the key players such as Boston Scientific, ASAHI INTECC Limited, and Cardinal health in this area adds up to the market growth.
Europe accounts for the second largest market due to the increasing rate of cardiovascular disorders and established medical device market. Additionally, the increasing government support and increasing healthcare infrastructure along with the increasing per capita income of individuals are driving the growth of the defibrillators pads market in Europe. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. This increasing older population is likely to increase the rising patient population because of them being prone to cardiovascular diseases. Furthermore, the U.S. and the U.K. are making it compulsory for certain sports arenas, government facilities, and institutes to store and maintain Automated External Defibrillators (AEDs), as unavailability of defibrillators is the most common cause of sudden cardiac arrest.  These initiatives are likely to accelerate the market growth of defibrillators pads as they are directly linked to defibrillators.
Asia Pacific is the fastest growing market for defibrillators pads whose growth is attributed to the rising population and improving the standard of living. Additionally, the increasing healthcare spending and demand for new and innovative treatment options are likely to drive the growth of the market. India, Singapore, Australia, and China are the major contributors to the market growth due to the rapid development of healthcare infrastructure, the presence of regional headquarters of key players in these regions and increasing demand for diagnostic services.
On the other hand, the Middle East and Africa is expected to witness a slow growth due to limited access to healthcare facilities and affordability issues among the population. In the Middle East, the growth of the market is driven by Saudi Arabia and the United Arab Emirates because of the well-established healthcare infrastructure, awareness for good health among the residents, as well as accessibility to modern medical technology methods.
Segmentation
The global defibrillators pads market is segmented on the basis of product, age group, distribution channel, and end-user. According to the product, the market is segmented into manual external, manual internal, automatic external, and others.
Considering the age group, the market is segmented into pediatric defibrillator pads and adult defibrillator pads.
According to the distribution channel, the market is segmented into online pharmacy, retail pharmacy, hospital pharmacy, and others.
On account of end-user, the market is segmented into pre-hospital services, hospitals and clinics, alternate care facilities, the public access market, and the home healthcare services market. Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Key Players
Some of the key players in the Defibrillators pads market are Medtronic, Cardiac Science Corporation, Koninklijke Philips N.V., Boston Scientific Corporation, Stryker Corporation, Cardinal Health, Biotronik SE & Co. KG, Defibtech, LLC., and  Mindray Medical.
Posted by at No comments:

Glioma Diagnosis and Treatment Market Leading Glioma Diagnosis and Treatment Market Key Developments Trends, Analysis And Forecasts Till 2023

Market Scenario
A Glioma is a type of tumor that originates in the brain and is also known as a primary brain tumor. There are numerous types of gliomas which are entitled based on the origin of the cell type including oligodendrogliomas, astrocytoma, ependymomas, and glioblastoma. Nearly 33 percent of all brain tumors are gliomas. These originate in glial cells surrounding the neurons in the brain.
Global Glioma Diagnosis and Treatment market is expected to grow at a CAGR of approximately 10.1% during the forecast period, 2017–2023.
According to the American Brain Tumor Association, more than 79,000 new cases of primary brain tumors were diagnosed in 2017 with 24.7% of those being gliomas.
Brain tumors are one of the prominent causes of cancer among children and teenagers. Glioma is the most common type of brain tumor which accounts for approximately half of all the astrocytoma. The increasing occurrence of glioblastoma over the years is responsible for the growth of the glioma diagnosis and treatment market. The upcoming drug launches and developments in research are instrumental for the growth of the market. In addition, the current unmet need is expected to drive the gliomas industry over the forecast period. Changing financial demands and access to healthcare facilities are some of the factors that are constraining the market growth.
Astrocytoma is the most common types of glioma diagnosed worldwide, as more than 30% of all the diagnosed cases with brain tumors are astrocytoma. These types of tumors are not curable as they spread easily through normal brain tissue. The American Brain Tumor Association has evaluated that around 7% of all the primary brain tumors represent astrocytoma.
The expanding market for the treatment of brain cancer-associated symptoms, the increasing prevalence of brain cancer, and innovations in drug delivery to brain cancer cells are some of the key factors augmenting the demand in the global glioma diagnosis and treatment market. Furthermore, the introduction of novel therapies coupled with various organizations generating awareness and increasing geriatric population are factors driving the growth of the global glioma diagnosis and treatment market.
Key Players
Some of the key players in the global glioma diagnosis and treatment market are Thermo Fisher Scientific Inc. (U.S.), Emcure Pharmaceuticals Ltd. (India), Sigma-Aldrich Co. (U.S.), Pfizer Inc. (U.S.), Taj Pharmaceuticals Limited (India), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), GE Healthcare (U.S.), Siemens Healthineers (U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Merck & Co., Inc. (U.S.), F. Hoffmann-Le Roche AG (Switerland), Arbor Pharmaceuticals, LLC (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Amneal Pharmaceuticals. LLC (U.S.), AstraZeneca (UK), Carestream Health (U.S.), Hitachi Medical Corporation (U.S.), and others.
Segmentation
Geographically, the Americas glioma diagnosis and treatment market is segmented into two major regions, namely, North America and South America.
North America accounted for the largest share of the global gliomas industry in 2016, and the trend is expected to continue over the projected period. Moreover, it is anticipated that about 80,000 new cases will be registered related to brain tumors in the year 2017 which includes 26,000 primary malignant brain tumors.
The Americas glioma diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, grade, location, and end-user.
Regional Analysis
The global glioma diagnosis and treatment market consist of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
Growing medical tourism and prevalence of metastatic tumors that require surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of brain tumors are similarly supporting the growth of this market.
The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of brain tumor, rising awareness among people, and increasing healthcare expenditure. Brain tumor is the third most common types of cancer in adults in North America. According to the North American Brain Tumor Coalition over 44,500 people in the U.S. were diagnosed with a primary tumor in the brain in 2014. Thus, the increasing incidences of primary brain tumor support the growth of the malignant glioma treatment in North America.  
Asia Pacific is estimated to be the most lucrative market for gliomas due to the increasing occurrence of brain tumors in Asia Pacific countries such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.

Posted by at No comments:

Worldwide Picture Archiving and Communications Systems Market Top 10 Players Universal Analysis, Industry Demand And 2023 Forecast

Market Scenario:
Radiology imaging solutions have generated a significant return on its healthcare IT investment by implementing Exa’s Voice Recognition in place of traditional transcriptionists, and their productivity has increased by 400%.           
Picture Archiving and Communication System (PACS) is a modality of the medical imaging technology used specifically for image transmission from the site of image acquisition to other locations. The technology is convenient to access multiple modalities such as radiographs, CT scan, MRI, ultrasound, and others.
It is noted that the increasing prevalence of chronic diseases and the growing geriatric population are the key factors driving the PACS market. The increasing burden of chronic diseases has been observed in different parts of the world. Population in the low socio-economic group is mostly found to get affected by these chronic diseases. According to the report published in the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults are dealing with at least one type of cardiovascular disease. The prevalence of type-2 diabetes, obesity, and cardiovascular diseases has increased rapidly in the recent years, suggested by a study published in the BMC Public Health in 2017.
Various other factors such as supportive investments and funds provided by government and private bodies, rising demand for early diagnosis, technological advancements in the medical imaging devices, rising incidence of cancer, improving regulatory framework, growing research funding, unmet medical needs, rising competition among market players, and increasing government assistance are continuously contributing to the growth of the global PACS market.
Despite these drivers, there are some issues associated with the PACS market. The high cost associated with the technology, lack of healthcare insurance, lack of awareness, and poor healthcare system in low- and middle-income countries may hamper the growth of the market.
It is estimated that the Picture Archiving and Communications Systems (PACS) market growth is expected to boost at a CAGR 7.0% during the forecast period of 2017–2023.
Key Players
Some of the key players in the global Picture Archiving and Communications Systems (PACS) market are Advanced Data Systems, Agfa-Gevaert N.V., Allscripts Healthcare Solutions, Inc., ALTA VISTA TELERADIOLOGY, Argus Radiology, Avreo, Inc., Brit Systems, Comarch SA, Cybernet Medical Corporation, FujiFilm Medical Systems, GE Healthcare, Global Diagnostics, INFINITT Healthcare, Konica Minolta Healthcare Americas Inc., McKesson Corporation,Inc., ONRAD, Inc., Pacshealth, LLC, PERFECT IMAGING, LLC, RamSoft, Inc., Radiology Imaging Solutions, Scimage, Inc., Sectra Imtec AB, Sectra Imtec AB, Siemens Healthineers, Singular Medical Technologies, StatRad, LLC, Telediagnostics Services Pvt. Ltd., Telerad Tech Private Limited, Virtual Radiology (vRAD), and others
Segmentation
The global Picture Archiving and Communications Systems (PACS) market is segmented on the basis of type, component, imaging type, delivery mode, and end-user.
On the basis of the type of imaging type, the market is classified as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), nuclear imaging, X-ray, and ultrasound.
On the basis of end-user, the market is classified as hospitals and clinics, healthcare centers, imaging centers, diagnostic centers, clinical research institutions, and others.
On the basis of delivery mode, the market is classified as cloud-based (SAAS) delivery mode, web-hosted (On-Demand) delivery mode, and on-premise mode.
On the basis of type, the market is classified as oncology PACS, cardiology PACS, dental PACS, orthopedics PACS, and others.
On the basis of components, the market is classified as hardware, software, and services. The hardware segment is further classified as access devices, peripherals, servers, storage devices, and networking devices. The services segment is further classified as consulting, implementation services, post-sales and maintenance services, and training services.
Regional Analysis
Asia Pacific is the fastest growing Picture Archiving and Communications Systems (PACS) market owing to a huge patient pool, increasing demand for diagnosis, and development in the healthcare IT sector. According to IBEF, the Healthcare Information Technology (IT) market was valued at USD 1 billion in 2016 which is estimated to grow 1.5 times by 2020.
The Americas dominates the Picture Archiving and Communications Systems (PACS) market owing to the rising demand for early diagnosis, rising prevalence of chronic diseases, well-developed technology, high healthcare expenditure, and the presence of leading players. Owing to the rising demand for imaging devices, various market players are coming up with advanced technology. For instance, on March 26, 2018, Singular Medical Technologies (SMT), the U.S. based technology company announced two new additions to its PACStation suite of products. The PACStation-GO is a fully functional reading workstation, with two full-size diagnostic monitors and is completely portable.
Europe holds the second position in the Picture Archiving and Communications Systems (PACS) market. It is expected that the funding towards research and development expenditure and increasing competition among marketers are likely to drive the European market.
The Middle East and Africa holds the lowest share of the global Picture Archiving and Communications Systems (PACS) market due to low development, lack of technical knowledge, and poor medical facilities.
Browse More Detailes of the Report @
Posted by at No comments:
Subscribe to: Posts (Atom)